Fogarty Innovation Graduate Raydiant Oximetry Raises $5 Million in Oversubscribed Series A2 Financing Round to Support Clinical Study
Innovative technology designed to keep mothers and babies safe during childbirth.
November 3, 2021
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
View the latest clinical trials, studies, data, and updates.
Innovative Embolic Device Shows Promise for Interventional Oncology Drug Delivery
The GPX Embolic Device is under development and does not have marketing clearance or approval in any market at this time. For investigational use (in New Zealand) only. GPX-DOX Embolic Device is under development and does not have marketing clearance or approval in any market at this time.
November 2, 2021
VenoStent Embarks on Clinical Trial to Improve Success Rate of Vascular Surgery Outcomes
Tim Boire, CEO said, “After years of development, we are confident that our bioabsorbable wrap technology can have a positive impact on the lives of patients that require hemodialysis to sustain life.
October 26, 2021
CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study
The PVISION study is the perfect opportunity to demonstrate the importance of enhanced EP recording technology and AI algorithms in shaping the future of diagnosing, characterizing and treating complex arrhythmias.
October 26, 2021
STALIF C-Ti® Study Published Journal of Surgery & Anesthesia Research
The clinical study utilizing the STALIF C-Ti integrated cage-screw implants was performed in 145 patients and 12-month outcome scores demonstrated significant improvement in all available patient reported outcome scores collected (p<0.05 for all), including NDI, VAS neck, VAS left arm, and VAS right arm.
October 26, 2021
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
“This analysis provides the first clinical evidence that the Decipher Prostate classifier can help physicians and patients make critical, personalized treatment decisions in the post-biopsy, clinically high-risk prostate cancer setting,” said Elai Davicioni, Ph.D., Veracyte’s senior vice president of scientific and clinical operations, Urologic Cancers.
October 25, 2021